Medical Oncology

, Volume 20, Issue 4, pp 389–396 | Cite as

Mycosis fungoides/Sézary syndrome

A report of three cases treated with Campath-1H as salvage treatment
  • Silvana Capalbo
  • Mario Delia
  • Michela Dargenio
  • Arcangelo Liso
  • Daniela Diomede
  • Lucrezia Garofalo
  • Vincenzo Liso
Case Report

Abstract

We report the use of Alemtuzumab (Campath-1H) as salvage treatment in three patients with advanced mycosis fungoides/Sézary syndrome who had previously been treated with conventional chemotherapy. Two patients (case 1 and case 2), aged 42 and 68 yr, respectively, were heavily pretreated (more than three prior therapy regimens, including autologous transplant in case 2) and refractory to conventional chemotherapy, and the third patient (case 3), aged 80 yr, who had refused any chemotherapy, had been resistant to treatment with cyclosporine and steroids. Campath-1H was administered intravenously, after an escalating dose from 3 to 10 mg, at the dose of 30 mg, three times weekly, to a total dose of 1080, 223, and 480 mg, respectively. The patients with Sézary syndrome (case 2 and case 3) showed clearance of circulating Sézary cells and clinical improvement of the skin lesions after 2 wk of treatment. Two patients (case 1 and case 3) completed the treatment (12 and 6 wk) without significant toxicity, the former achieving a partial response and the latter a clinical complete response. The patient (case 2), who suffered from ischemic cardiopathy and diabetes, quickly achieved a clinical improvement of the Sézary syndrome, but he died because of a myocardial infarction after 3 wk of treatment.

Our report shows that the treatment with Campath-1H is active even in patients with advanced refractory mycosis fungoides/Sézary syndrome. Further clinical observations on a larger cohort of patients are needed to establish if Campath-1H may have a role as first line therapy in addition to conventional therapy including chemotherapy.

Key Words

Mycosis fungoides/Sézary syndrome monoclonal antibody Campath-1H 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Diamandidou E, Cohen PR, Kuzrock R. Mycosis fungoides and Sézary syndrome. Blood 1996;88(7):2385–2409.PubMedGoogle Scholar
  2. 2.
    Bunn PA Jr, Lamberg SI. Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep 1979;63(4):725–728.PubMedGoogle Scholar
  3. 3.
    Green SB, Byar DP, Lamberg SI. Prognostic variables in mycosis fungoides. Cancer 1981;47(11):2671–2677.PubMedCrossRefGoogle Scholar
  4. 4.
    Hoppe RT, Wood GS, Abel EA. Mycosis fungoides and Sézary syndrome:pathology, staging and treatment. Curr Probl Cancer 1990;14:293–295.PubMedGoogle Scholar
  5. 5.
    Foss FM, Sausville EA. Prognosis and staging of cutaneous T cell lymphoma. Hematol Oncol Clin North Am 1995;9(5):1011–1019.PubMedGoogle Scholar
  6. 6.
    Bunn PA, Hoffman SJ, Norris D, Golitz LE, Aelig JL, Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and Sézary syndrome) Ann Intern Med 1994;121(8):595–602.Google Scholar
  7. 7.
    Edelson R, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med 1987;316(6):297–303.PubMedCrossRefGoogle Scholar
  8. 8.
    Altomare GF, Capella GL, Pigatto PD, Finzi AF. Intramuscular low dose alpha 2-B interferon and etretinate for treatment of mycosis fungoides. Int J Dermatol 1993;32(2):138–141.PubMedCrossRefGoogle Scholar
  9. 9.
    Foss FM, et al. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 1994;12(10):2051–2059.PubMedGoogle Scholar
  10. 10.
    Fierro MT, et al. Combination of etoposide, idarubicin, cyclophosfamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma. Dermatology 1997;194(3):268–272.PubMedCrossRefGoogle Scholar
  11. 11.
    Sinha AA, Heald P. Advanced in the management of cutaneous T-cell lymphoma. Dermatol Clin 1998;16(2):301–311.PubMedCrossRefGoogle Scholar
  12. 12.
    Duvic M, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma:multinational phase II–III trial results. J Clin Oncol 2001:19(9):2456–2471.PubMedGoogle Scholar
  13. 13.
    Lundin J, et al. Campath-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin’s lymphomas:a phase II multicenter study. J Clin Oncol 1998;16(10):3257–3263.PubMedGoogle Scholar
  14. 14.
    Pawson R, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997;15(7):2667–2672.PubMedGoogle Scholar
  15. 15.
    Österborg A, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 1997;15(4):1567–1574.PubMedGoogle Scholar
  16. 16.
    DelleKarth G. et al. Clearance of PCR-detectable lymphoma cells from the peripheral blood, but not bone marrow, after therapy with CAMPATH-1H. Am J Hematol 1995;50(2):146–147.PubMedCrossRefGoogle Scholar
  17. 17.
    Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47(1):207–214.PubMedCrossRefGoogle Scholar
  18. 18.
    Fuks ZY, Bagshaw MA, Farber EM. Prognostic signs and the management of the mycosis fungoides. Cancer 1973;32(6):1385–1395.PubMedCrossRefGoogle Scholar
  19. 19.
    Sausville EA, et al. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups. Ann Intern Med 1988;109(5):372–382.PubMedGoogle Scholar
  20. 20.
    Bernengo MG, et al. Prognostic factors in Sézary syndrome:a multivariate analysis of clinical, hematological and immunological features. Ann Oncol 1998;9(8):857–863.PubMedCrossRefGoogle Scholar
  21. 21.
    Diamandidou E, Colome M, Fayad L, Duvic M, Kurzrock R. Prognostic factor analysis in mycosis fungoides/Sézary syndrome. J Am Acad Derm 1999;40(6 Pt 1):914–924.PubMedCrossRefGoogle Scholar
  22. 22.
    Siegel RS, Pandolfino T, Guitart J, Rosen S, Kuzel TM. Primary cutaneous T-cell lymphoma:review and current concepts. J Clin Oncol 2000;18:2908–2925.PubMedGoogle Scholar
  23. 23.
    de Coninck EC, Kim YH, Varghese A, Hoppe RT. Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol 2001;19(3):779–784.PubMedGoogle Scholar
  24. 24.
    Dearden CE, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Med Oncol 2002;19(Suppl.):S27-S32.PubMedCrossRefGoogle Scholar
  25. 25.
    Lundin J, et al. Phase II study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome. Blood 2003:101:4267–4272.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2003

Authors and Affiliations

  • Silvana Capalbo
    • 3
  • Mario Delia
    • 3
  • Michela Dargenio
    • 3
  • Arcangelo Liso
    • 1
  • Daniela Diomede
    • 3
  • Lucrezia Garofalo
    • 2
  • Vincenzo Liso
    • 3
  1. 1.Policlinico MonteluceHematology, University of PerugiaPerugia
  2. 2.Dermatology, University of BariBariItaly
  3. 3.Hematology, University of Bari, PoliclinicoBariItaly

Personalised recommendations